The metabolism or atropine in man

Meer, M. J. Van Der; Hundt, H. K. L.; Müller, F. O.

doi:10.1111/j.2042-7158.1986.tb04494.x

Cited by 27 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study the reported systemic bioavailability of atropine in healthy individuals ranged from 19% to 95% [ 45 ]. The largest amount of the drug is metabolized by enzymatic hydrolysis, particularly in the liver and 13–50% of the molecule is excreted unmodified in the urine [ 46 , 47 ].…”

Section: Resultsmentioning

confidence: 99%

The Role of Atropine in Preventing Myopia Progression: An Update

et al. 2022

View full text Add to dashboard Cite

Several approaches have been investigated for preventing myopia progression in children and teenagers. Among them, topical atropine has shown promising results and it is being adopted in clinical practice more and more frequently. However, the optimal formulation and treatment algorithm are still to be determined. We discuss the pharmacokinetic, pharmacodynamic, clinical, and tolerability profile revealed first by the multicenter, randomized ATOM 1 and 2 trials and, more recently, by the LAMP Study. Results from these trials confirmed the efficacy of low-concentration atropine with a concentration-dependent response. Although atropine at 0.025% and 0.05% concentrations has shown the most encouraging results in large-scale studies, these formulations are not yet commonplace in worldwide clinical practice. Moreover, their rebound effect and the possibility of reaching a stabilization effect have not been fully investigated with real-life studies. Thus, further larger-scale studies should better characterize the clinical efficacy of atropine over longer follow-up periods, in order to define the optimal dosage and treatment regimen.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of Atropine in Preventing Myopia Progression: An Update

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Very little information is available about the toxicity of tropic acid and even less is available about any potential ocular toxicity. In the human body, atropine metabolism produces small (3%) amounts of tropic acid [ 58 ] and atropine is mostly excreted unchanged in the urines. During ophthalmic administrations in rabbits, it has been shown that atropine has good ocular bioavailability via both transcorneal and transconjunctival-scleral routes [ 59 ].…”

Section: Discussionmentioning

confidence: 99%

Stability of Ophthalmic Atropine Solutions for Child Myopia Control

et al. 2020

View full text Add to dashboard Cite

Myopia is an ophthalmic condition affecting more than 1/5th of the world population, especially children. Low-dose atropine eyedrops have been shown to limit myopia evolution during treatment. However, there are currently no commercial industrial forms available and there is little data published concerning the stability of medications prepared by compounding pharmacies. The objective of this study was to evaluate the stability of two 0.1 mg/mL atropine formulations (with and without antimicrobiobial preservatives) for 6 months in two different low-density polyethylene (LDPE) multidose eyedroppers. Analyses used were the following: visual inspection, turbidity, chromaticity measurements, osmolality and pH measurements, atropine quantification by a stability-indicating liquid chromatography method, breakdown product research, and sterility assay. In an in-use study, atropine quantification was also performed on the drops emitted from the multidose eyedroppers. All tested parameters remained stable during the 6 months period, with atropine concentrations above 94.7% of initial concentration. A breakdown product (tropic acid) did increase slowly over time but remained well below usually admitted concentrations. Atropine concentrations remained stable during the in-use study. Both formulations of 0.1 mg/mL of atropine (with and without antimicrobial preservative) were proved to be physicochemically stable for 6 months at 25 °C when stored in LDPE bottles, with an identical microbial shelf-life.

show abstract

“…, tropic acid and tropine). 66 Fig. 6 represents the highest response to ( S )-hyoscyamine, stemming from the high complementarity between the target alkaloid and the cavities of the MIP.…”

Section: Resultsmentioning

confidence: 99%